Boehringer and Eli Lilly meet primary endpoints in heart failure treatment studies

In a new phase III trial, Boehringer Ingelheim and Eli Lilly have received positive results with the diabetes drug Jardiance for treating chronic heart failure.
Photo: Boehringer Ingelheim/ PR
Photo: Boehringer Ingelheim/ PR

Boehringer Ingelheim and Eli Lilly have received breakthrough results in their Empreror-Preserved phase III study of type 2 diabetes drug Jardiance. It is the first succesful treatment for chronic heart failure, or a weak pulse with preserved ejection fraction.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading